Jago Grahak Jago

Jago Grahak Jago Logo

Zydus launches anti-cancer generic drug olaparib in India

Mar 14,2024

Zydus Lifesciences on Wednesday said it has launched olaparib, a PARP inhibitor, under the brand name IBYRA in India, making advanced cancer treatment accessible to all.

PARP (poly-ADP ribose polymerase) is a protein that helps damaged cells to repair themselves. As a cancer treatment, PARP inhibitors block the PARP from doing its repair work in cancer cells and the cell dies.

The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for a more tailored and effective treatment approach, the company said in a stock exchange filing.

The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for a more tailored and effective treatment approach.

To help identify the right patients and facilitate access, Zydus has collaborated with MedGenome for comprehensive HRD testing . This along with a year-long treatment of IBYRA has been capped at Rs. 3 lakhs as compared to the cost of around Rs. 72 lakhs by the innovator.

Out of 14 lakh newly diagnosed cancer patients in India, nearly 2.75 lakh patients are diagnosed with breast, ovarian, prostate and pancreatic cancers as per Globocan 2022 data. Amongst these patients, those who are diagnosed as HRD positive or with BRACA mutation need to be administered this PARP inhibitor which can delay the progression of the disease. IBYRA is a next gen targeted therapy for HRD-positive and BRACA-positive cancer patients.

Source: Pharma

Leave a Comment

Your email address will not be published. Required fields are marked *